In-vitro activities of various antibiotics, alone and in combination with amikacin against Pseudomonas aeruginosa.
The in-vitro activities of various antibiotics, either alone or in combination with amikacin were assessed in clinical isolates of Pseudomonas aeruginosa. Clinically relevant synergic interactions were most frequent with piperacillin (92%), ceftazidime (87%) and aztreonam (84%), and less frequent with imipenem (35%). Ciprofloxacin-amikacin showed only an additive effect.
Gerçeker
A A
AA
Department of Pharmaceutical Microbiology, Faculty of Pharmacy, University of Istanbul, Turkey.
Gürler
B
B
D000583:Amikacin / Q000494:pharmacology*; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001398:Aztreonam / Q000494:pharmacology; D002442:Ceftazidime / Q000494:pharmacology; D002939:Ciprofloxacin / Q000494:pharmacology; D004357:Drug Synergism; D004359:Drug Therapy, Combination / Q000494:pharmacology*; D015378:Imipenem / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D010878:Piperacillin / Q000494:pharmacology; D011550:Pseudomonas aeruginosa / Q000187:drug effects*
D000900:Anti-Bacterial Agents; D002939:Ciprofloxacin; D015378:Imipenem; D000583:Amikacin; D002442:Ceftazidime; D001398:Aztreonam; D010878:Piperacillin